| Patient | Billie Holiday |
|---|---|
| Date of birth | 1915-04-07 |
| Identifiers | MRN HR-ML010-SYN-TD; SSN (made up) 000-10-4472 |
| Document date | 1948-05-26 |
| Author | Constance Mayfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Five-week recovery review and second hepatitis B vaccine. [S]
Ms. Holiday returns five weeks after starting buprenorphine, after a three-week tour. She has taken 16 mg every morning without a gap and has used no heroin or other opioids. Cravings are now brief and come mostly late at night after a show; she calls her peer recovery coach when they do. She takes acamprosate most days but sometimes forgets the midday dose. She has cut down to two or three drinks on performance nights. She spoke with her counselor by phone each week while away. Her mood is a little better. She kept the naloxone in her bag and has not needed it. [S]
| Element | Detail |
|---|---|
| Buprenorphine | 16 mg daily, no gaps |
| Opioid use | None |
| Cravings | Brief, late at night; she calls her peer coach |
| Alcohol | Two or three drinks on performance nights |
| Acamprosate | Most days; misses some midday doses |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | Constipation settled; no nausea |
| Psychiatric | Positive | Mood somewhat low at times; no thoughts of suicide or self-harm |
| Neurological | Negative | No tremor or unsteadiness |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily | One film under the tongue daily after a 4 mg first dose | Sublingual route | 1948-04-20 to 1948-04-27 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily | Two films under the tongue once daily | Sublingual route | 1948-04-27 | active | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response | Nasal route | 1948-04-20 | active | S |
| Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times daily | Two tablets by mouth three times daily | Oral route | 1948-04-27 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1948-04-20 to 1948-10-19 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1948-05-26 | Body height | 165 | cm | S |
| 1948-05-26 | Body weight | 68.6 | kg | S |
| 1948-05-26 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 1948-05-26 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1948-05-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1948-05-26 | Heart rate | 74 | /min | S |
| 1948-05-26 | Respiratory rate | 14 | /min | S |
| 1948-05-26 | Body temperature | 36.6 | Cel | S |
| 1948-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1948-05-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 10-40 U/L | Normal | S |
| 1948-05-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-56 U/L | Normal | S |
| 1948-05-26 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 5-40 U/L | High | S |
| 1948-05-26 | Phosphatidylethanol [Mass/volume] in Blood | 96 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 1948-05-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S |
Vital signs recorded on 1948-05-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 118/76, pulse 74 |
| Abdomen | Soft and non-tender; no liver enlargement |
| Psychiatric | Engaged; no signs of intoxication or withdrawal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use | active | confirmed | F11.20 | S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use. |
| Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, adherence, cravings, withdrawal, and side effects | Every visit | Completed today | 16 mg daily without gaps; brief cravings; no sedation |
| Self-management | Visit frequency | Every 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stable | Deferred | Four weeks since the one-week visit, longer than the one to two weeks advised in the first month, because she was on tour; the planned call-in visit at two weeks did not happen. Weekly counseling calls continued, and no harm resulted. Corrective action: video check-ins every two weeks between visits while touring |
| Laboratory | Urine drug testing, including fentanyl, explained as part of care rather than as a test of trust | At the start, then about monthly early in treatment and as needed | Completed today | Buprenorphine and norbuprenorphine only |
| Medication safety | Prescription drug monitoring program check | Before each buprenorphine prescription | Completed today | No other prescriptions |
| Medication safety | Naloxone at home and in her bag, and a trained companion | At the start; check and replace at each visit | Completed today | In her bag and at home; not used |
| Self-management | Overdose prevention: never using alone and fentanyl test strips | Every visit | Completed today | Reviewed |
| Self-management | Counseling and peer recovery support | Offered to everyone; not a condition of medication | Completed today | Weekly counseling by phone on tour; peer coach by phone |
| Survey | Drinking and PEth | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 96 ng/mL, from 312; two or three drinks on performance nights |
| Medication safety | Acamprosate adherence and kidney function | Kidney function before starting; adherence every visit | Completed today | Missing some midday doses; reminder set |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine daily |
| Laboratory | Liver tests (AST, ALT, GGT, albumin, bilirubin) | At intake, then every 1 to 3 months while drinking is heavy, and yearly | Completed today | AST 38, ALT 30, GGT 52 U/L, improving |
| Laboratory | FIB-4 fibrosis score | At intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 years | Up to date | 1.18 at intake; repeat at six months |
| Imaging | Vibration-controlled transient elastography | If FIB-4 is 1.3 or higher | Not indicated | FIB-4 below 1.3 |
| Self-management | Hepatitis A and B vaccines | Hepatitis B two doses 4 weeks apart; hepatitis A two doses 6 months apart | Completed today | Hepatitis B dose 2 given today; hepatitis A dose 2 at six months |
| Survey | Depression screen (PHQ-9) | At intake and at each recovery visit while symptoms are present | Completed today | PHQ-9 7, item 9 scored 0 |
| Survey | Suicide and overdose risk review, safety plan, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan and the 988 Suicide & Crisis Lifeline in her phone |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]
Guideline basis: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Video check-ins every two weeks while touring. Three-month visit with PEth, liver tests, and the PHQ-9. Next scheduled visit 1948-07-20: three-month review after a return to opioid use: adjusting the recovery plan. [S]